MAKING A NEW WAVE WITH
PREDICTIVE BIOMARKERS
We Hope to Make a World Free From Cancer by Developing
First-in-Class Anticancer Drugs Based on Predictive Biomarkers
We Strive to Make
the World Healthier
We develop first-in-class anticancer drugs based on predictive biomarkers for unmet medical needs.
By utilizing clinical information from one of the largest hospital in South Korea, we hope to make a world free from cancer.
Our dedicated researchers are making ceaseless efforts to develop new anticancer drugs.
We will continue to strive for the healthy life of mankind.
Corporate video
Our Scientific Approach
-
Patient Population
-
Biomarker Identification
-
Novel Anticancer Drug
Our researchers are developing predictive biomarkers that could identify patient's drug response to a certain therapy.
As a result, we can shorten the lead time, reduce the development cost and
increase the success rate in first-in-class anticancer drugs.
Press Relese
More-
Wellmarker Bio Announced Successful First Subject Dosed in Phase I Clinical Study ...
Wellmarker Bio Co., Ltd (WMBIO), a biopharmaceutical company with fully-integrated capabilities in discovery, development of new anticancer dr...
2021-07-20 -
Wellmarker Bio’s R&D Center Recognized for an Outstanding Research Capabilit...
The Ministry of Science and ICT of Korea (MSIT) announced that 29 companies were designated as an ‘Excellent Corporation R&D Center’ b...
2021-06-29 -
Wellmarker Bio Presents Preclinical Data for WM-A1 at the AACR Annual Meeting 2021
Wellmarker Bio, a company committed to discovering and developing first-in-class anti-cancer drugs with predictive biomarkers, presented precl...
2021-04-13